Literature DB >> 21497004

Below what FEV1 should arterial blood be routinely taken to detect chronic respiratory failure in COPD?

Diego A Rodríguez1, Lluis Jover, Mitra B Drakulovic, Federico P Gómez, Josep Roca, Joan Albert Barberà, Peter D Wagner, Roberto Rodríguez-Roisin.   

Abstract

INTRODUCTION: To diagnose and assess chronic respiratory failure in stable chronic obstructive pulmonary disease (COPD) the measurement of arterial blood gases (ABG) is required. It has been suggested that ABG be determined for this purpose when FEV1 ranges between 50% and 30% predicted, but these thresholds are not evidence-based.
OBJECTIVE: To identify the post-bronchodilator (BD) FEV₁ and arterial oxygen saturation (SaO(2)) values that provide the best sensitivity, specificity, and likelihood ratio (LR) for the diagnosis of hypoxaemic and/or hypercapnic chronic respiratory failure in stable COPD.
METHODS: A total of 150 patients were included (39 with PaO₂ < 60 mmHg [8 kPa], 14 of them with a PaCO₂ ≥ 50 mmHg [6.7 kPa]). The best post-BD FEV(1) and SaO(2) cut-off points to predict chronic respiratory failure were selected using the PC and the Receiver Operating Characteristics (ROC) curves.
RESULTS: A post-BD FEV(1) equal to 36% and an SaO(2) of 90% were the best predictive values for hypoxaemic respiratory failure and a post-BD FEV(1) equal to 33% for the hypercapnic variant. An FEV(1) ≥ 45% ruled out hypoxaemic respiratory failure.
CONCLUSION: A post-BD FEV(1) of 36% is the best cut-off point to adequately predict both hypoxaemic and hypercapnic respiratory failure in the patient with stable COPD. For its part, an SaO(2) of 90% is the best value for isolated hypoxaemic failure. These values could be considered for future clinical recommendations/guidelines for COPD. 2010 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21497004     DOI: 10.1016/j.arbres.2011.02.009

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  2 in total

Review 1.  Hypercapnia in COPD: Causes, Consequences, and Therapy.

Authors:  Balázs Csoma; Maria Rosaria Vulpi; Silvano Dragonieri; Andrew Bentley; Timothy Felton; Zsófia Lázár; Andras Bikov
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

2.  Development and Relevance of Hypercapnia in COPD.

Authors:  Chirag Dave; Simon Wharton; Rahul Mukherjee; Bandar M Faqihi; Robert A Stockley; Alice M Turner
Journal:  Can Respir J       Date:  2021-02-22       Impact factor: 2.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.